Adjuvant Radiotherapy After Radical Cystectomy for Muscle-invasive Bladder Cancer: A Phase 2 Trial—Results of Secondary Endpoints

IF 5.6 2区 医学 Q1 UROLOGY & NEPHROLOGY European urology focus Pub Date : 2025-07-01 Epub Date: 2025-02-19 DOI:10.1016/j.euf.2025.02.005
Flor Verghote , Elke Rammant , Piet Dirix , Charles Van Praet , Charlien Berghen , Sara Junius , Nick Liefhooghe , Leen Noé , Piet Ost , Karel Decaestecker , Geert Villeirs , Alexander Decruyenaere , Kathia De Man , Sofie Verbeke , Daan De Maeseneer , Valérie Fonteyne
{"title":"Adjuvant Radiotherapy After Radical Cystectomy for Muscle-invasive Bladder Cancer: A Phase 2 Trial—Results of Secondary Endpoints","authors":"Flor Verghote ,&nbsp;Elke Rammant ,&nbsp;Piet Dirix ,&nbsp;Charles Van Praet ,&nbsp;Charlien Berghen ,&nbsp;Sara Junius ,&nbsp;Nick Liefhooghe ,&nbsp;Leen Noé ,&nbsp;Piet Ost ,&nbsp;Karel Decaestecker ,&nbsp;Geert Villeirs ,&nbsp;Alexander Decruyenaere ,&nbsp;Kathia De Man ,&nbsp;Sofie Verbeke ,&nbsp;Daan De Maeseneer ,&nbsp;Valérie Fonteyne","doi":"10.1016/j.euf.2025.02.005","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and objective</h3><div>Patients with muscle-invasive bladder cancer (MIBC) who develop a recurrence after radical cystectomy (RC) have poor outcomes. This study aims to evaluate the safety and efficacy of adjuvant radiotherapy (ART) in mitigating pelvic recurrences in high-risk MIBC patients. We report on survival outcomes, health-related quality of life (HRQoL), and hematological toxicity for these patients.</div></div><div><h3>Methods</h3><div>A multicentric phase 2 trial was conducted from August 2014 to October 2020, in which 72 high-risk MIBC patients received ART after RC. High risk was defined by the presence of one or more of the following criteria: pT3 stage and lymphovascular invasion, pT4 stage, fewer than ten lymph nodes removed, positive lymph nodes, and positive surgical margins. Using intensity-modulated radiotherapy, patients with pelvic lymph nodes ± cystectomy bed (in case of a positive surgical margin) received 50 Gy in 25 fractions. Outcomes were local relapse-free rate (LRFR), clinical relapse-free survival (CRFS), overall survival (OS) (Kaplan-Meier statistics), HRQoL (European Organisation for Research and Treatment of Cancer QLQ-C30/QLQ-BLM30 surveys), and hematological toxicity (Common Terminology Criteria for Adverse Events grading).</div></div><div><h3>Key findings and limitations</h3><div>The median follow-up of patients without a recurrence was 39 mo. At 2 and 5 yr, LRFRs were 81% (95% confidence interval [CI] 71–91%) and 79% (95% CI 68–89%), CRFS rates were 32% (95% CI 21–42%) and 20% (95% CI 11–30%), and OS rates were 48% (95% CI 36–59%) and 34% (95% CI 22–45%), respectively. At the end of ART, several symptoms worsened, most returning to baseline within the first few months. Diarrhea showed the greatest deterioration, recovering to baseline score only partially. Hematological toxicity of incidence grade ≥2 included lymphopenia (75%), neutropenia (2%), thrombopenia (2%), and anemia (17%). Limitations include the single-arm design and the limited availability of blood samples and surveys.</div></div><div><h3>Conclusions and clinical Implications</h3><div>ART after RC is well tolerated and leads to a favorable local control rate, supporting its use in clinical practice.</div></div>","PeriodicalId":12160,"journal":{"name":"European urology focus","volume":"11 4","pages":"Pages 595-602"},"PeriodicalIF":5.6000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European urology focus","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2405456925000422","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/19 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background and objective

Patients with muscle-invasive bladder cancer (MIBC) who develop a recurrence after radical cystectomy (RC) have poor outcomes. This study aims to evaluate the safety and efficacy of adjuvant radiotherapy (ART) in mitigating pelvic recurrences in high-risk MIBC patients. We report on survival outcomes, health-related quality of life (HRQoL), and hematological toxicity for these patients.

Methods

A multicentric phase 2 trial was conducted from August 2014 to October 2020, in which 72 high-risk MIBC patients received ART after RC. High risk was defined by the presence of one or more of the following criteria: pT3 stage and lymphovascular invasion, pT4 stage, fewer than ten lymph nodes removed, positive lymph nodes, and positive surgical margins. Using intensity-modulated radiotherapy, patients with pelvic lymph nodes ± cystectomy bed (in case of a positive surgical margin) received 50 Gy in 25 fractions. Outcomes were local relapse-free rate (LRFR), clinical relapse-free survival (CRFS), overall survival (OS) (Kaplan-Meier statistics), HRQoL (European Organisation for Research and Treatment of Cancer QLQ-C30/QLQ-BLM30 surveys), and hematological toxicity (Common Terminology Criteria for Adverse Events grading).

Key findings and limitations

The median follow-up of patients without a recurrence was 39 mo. At 2 and 5 yr, LRFRs were 81% (95% confidence interval [CI] 71–91%) and 79% (95% CI 68–89%), CRFS rates were 32% (95% CI 21–42%) and 20% (95% CI 11–30%), and OS rates were 48% (95% CI 36–59%) and 34% (95% CI 22–45%), respectively. At the end of ART, several symptoms worsened, most returning to baseline within the first few months. Diarrhea showed the greatest deterioration, recovering to baseline score only partially. Hematological toxicity of incidence grade ≥2 included lymphopenia (75%), neutropenia (2%), thrombopenia (2%), and anemia (17%). Limitations include the single-arm design and the limited availability of blood samples and surveys.

Conclusions and clinical Implications

ART after RC is well tolerated and leads to a favorable local control rate, supporting its use in clinical practice.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
肌肉浸润性膀胱癌根治性膀胱切除术后的辅助放疗:一项次要终点的2期试验结果。
背景和目的:肌肉侵袭性膀胱癌(MIBC)患者在根治性膀胱切除术(RC)后复发的预后较差。本研究旨在评价辅助放疗(ART)减轻高危MIBC患者盆腔复发的安全性和有效性。我们报告了这些患者的生存结局、健康相关生活质量(HRQoL)和血液学毒性。方法:2014年8月至2020年10月进行了一项多中心2期试验,其中72例高危MIBC患者在RC后接受了ART治疗。高风险被定义为存在以下一个或多个标准:pT3期和淋巴血管侵犯,pT4期,少于10个淋巴结切除,淋巴结阳性,手术切缘阳性。采用调强放疗,盆腔淋巴结±膀胱切除术床(手术切缘阳性)患者接受25次50 Gy放疗。结果包括局部无复发率(LRFR)、临床无复发生存期(CRFS)、总生存期(OS) (Kaplan-Meier统计)、HRQoL(欧洲癌症研究与治疗组织QLQ-C30/QLQ-BLM30调查)和血液学毒副作用(不良事件分级通用术语标准)。主要发现和局限性:无复发患者的中位随访时间为39个月。在2年和5年,LRFRs分别为81%(95%可信区间[CI] 71-91%)和79% (95% CI 68-89%), CRFS率分别为32% (95% CI 21-42%)和20% (95% CI 11-30%), OS率分别为48% (95% CI 36-59%)和34% (95% CI 22-45%)。在抗逆转录病毒治疗结束时,一些症状恶化,大多数在最初几个月内恢复到基线。腹泻表现出最大的恶化,仅部分恢复到基线评分。发生率≥2级的血液学毒性包括淋巴细胞减少(75%)、中性粒细胞减少(2%)、血小板减少(2%)和贫血(17%)。局限性包括单臂设计和血液样本和调查的有限可用性。结论及临床意义:术后ART耐受性良好,局部控制率良好,支持临床应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
European urology focus
European urology focus Medicine-Urology
CiteScore
10.40
自引率
3.70%
发文量
274
审稿时长
23 days
期刊介绍: European Urology Focus is a new sister journal to European Urology and an official publication of the European Association of Urology (EAU). EU Focus will publish original articles, opinion piece editorials and topical reviews on a wide range of urological issues such as oncology, functional urology, reconstructive urology, laparoscopy, robotic surgery, endourology, female urology, andrology, paediatric urology and sexual medicine. The editorial team welcome basic and translational research articles in the field of urological diseases. Authors may be solicited by the Editor directly. All submitted manuscripts will be peer-reviewed by a panel of experts before being considered for publication.
期刊最新文献
Minimally Invasive Surgical Therapies in Patients with Catheter-Dependent Urinary Retention: A Collaborative Mini-review. Tissue Penetration of Gemcitabine and Gemcitabine Phosphate Metabolites Following Gemcitabine Intravesical System Administration Versus Standard Intravesical Instillation in a Preclinical Minipig Model. Estimating the Effect of Finasteride on Kallikrein Marker Levels in Blood and the Use of Converted Markers in the Four-Kallikrein Model. PSA Assessment in Male LUTS/BPE - CON. Clinical Trial Protocol for the Apa/Enza-short Study: A Randomized Nationwide Study of Shortened 12-Month Duration of Androgen Receptor Signaling Agent in Combination With Androgen Deprivation Therapy in Patients With Metastatic Low-volume Castration-sensitive Prostate Cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1